Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial.

Authors
Publication date
1 September 2015
Publisher

Abstract

info:eu-repo/semantics/nonPublishe

    Similar works

    Full text

    thumbnail-image

    Available Versions

    DI-fusion

    redirect
    oaioai:dipot.ulb.ac.be:2013/22229...
    Last time updated on 23/02/2017

    DI-fusion

    redirect
    oaioai:dipot.ulb.ac.be:2013/24473...
    Last time updated on 23/02/2017